SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5400)9/25/1998 1:08:00 PM
From: Joe E.  Read Replies (3) | Respond to of 6136
 
Interesting Viramune results!!

The Wall Street Journal reported today that short interest in Agouron was 83,392 on 9/24/98 vs 2,000,730 on 8/28/98.

The shorts have left for now at least, and it looks like they made some money.



To: Steve Fancy who wrote (5400)9/25/1998 1:53:00 PM
From: Izzy  Read Replies (2) | Respond to of 6136
 
At first blush, I'm not impressed at all with the Viramune results (no PI used!); only 64% patients had nondectable VLs at 6 mos! In some respects, I feel sorry for these patients who have to go thru all these clinical trials looking for the "magic" pills when they could be on a known, effective PI combo treatment regimen that we know works, IMO. I don't recall; is AGPH giving a presentation at the ICAAC meeting?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News